Drug intelligence / Profile preview

APL A12

Development stage: Phase 1
Lead developer: VA Office of Research & Development
Modality: Peptides
Administration: Oral

Overview

APL A12 is an altered peptide ligand (APL) derived from the immunodominant epitope of type II collagen (CII), specifically residues 256-270. It was developed as an immunomodulatory therapy for rheumatoid arthritis (RA). The mechanism involves the induction of peripheral tolerance or bystander suppression by shifting the T-cell response from a pro-inflammatory Th1 phenotype (characterized by interferon-gamma production) to a regulatory or Th2/Th3 phenotype (characterized by IL-4, IL-10, and TGF-beta production). APL A12 is designed to enhance the suppressive function of CD4+ CD25+ regulatory T cells, thereby reducing the autoimmune attack on joint collagen.

Other names: collagen type II altered peptide ligand A12CII(256-270) A12

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on APL A12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL A12.

Explore the full profile